What is Novaerus?
Novaerus operates at the intersection of medical technology and environmental safety, specializing in advanced air purification solutions. The company utilizes its patented NanoStrike technology to neutralize airborne pathogens, including viruses and bacteria, providing a continuous disinfection mechanism. By deploying specialized hardware such as the Defend 400 and Defend 1050, Novaerus serves a diverse clientele ranging from healthcare facilities and dental clinics to educational institutions. Their market position is defined by a commitment to clinical-grade safety standards, ensuring that high-risk indoor spaces maintain optimal air quality through rigorous, science-backed filtration and inactivation processes.
How much funding has Novaerus raised?
Novaerus has raised a total of $10M across 1 funding round:
Private Equity
$10M
Private Equity (2014): $10M with participation from Polaris Partners
Key Investors in Novaerus
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors, providing deep operational expertise and strategic guidance to foster long-term innovation.
What's next for Novaerus?
With this major enterprise-level funding, Novaerus is poised to accelerate its market penetration and operational capacity. The strategic roadmap likely involves expanding the reach of its NanoStrike technology into new geographic territories and diversifying its product portfolio to meet the evolving demands of commercial and institutional sectors. As the global focus on indoor air safety remains a priority for public health, Novaerus is strategically aligned to capitalize on the growing demand for reliable, continuous air disinfection systems. The firm will likely prioritize scaling its manufacturing capabilities and strengthening its distribution networks to solidify its leadership in the medical-grade air purification market.
See full Novaerus company page
